Purpose of review: With the move toward development of disease modifying treatments,
there is a need for more specific diagnosis of early Alzheimer's disease (AD) and mild …

Background Preclinical prediction of Alzheimer disease (AD) is important and critical to
effective intervention. Plasma levels of amyloid-β (Aβ) peptides have been a principal focus …

To unlock the full potential of disease modifying treatments, it is essential to develop early
biomarkers for Alzheimer's disease (AD). For practical reasons, blood-based markers that …

Introduction Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD)
process yields conflicting results. The objective of the study was to assess plasma levels of …

Previous studies that have examined the potential for plasma markers to serve as
biomarkers for Alzheimer disease (AD) have studied single analytes and focused on the …

Background A practical biomarker is required to facilitate the preclinical diagnosis of
Alzheimer's disease (AD). Methods Plasma amyloid beta (Aβ) 1–40, Aβ1–42, Aβn–40, and …

Biomarker discovery is a major need for earlier dementia diagnosis. We evaluated a plasma
signature of amyloid, metallo-proteinases (MMPs), and inflammatory markers in a cohort of …

Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …

Alzheimer′ s disease is the most common form of dementia affecting millions of individuals
worldwide. It is currently diagnosed only via clinical assessments and confirmed by …

A blood-based protein biomarker, or set of protein biomarkers, that could predict onset and
progression of Alzheimer's disease (AD) would have great utility; potentially clinically, but …